Amgen has reported detailed results from the phase III ASPECCT ('763) trial comparing Vectibix (panitumumab) to Erbitux (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy. The study met its primary endpoint, demonstrating that panitumumab was non-inferior to cetuximab for overall survival.
These results were presented at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress in Amsterdam.
The prospective study showed that the median overall survival for patients treated with panitumumab was 10.4 months (range 9.4 months to 11.6 months) compared to 10 months (range 9.3 months to 11.0 months) for patients treated with cetuximab (95 percent CI, 0.84-1.11, p=0.0007).
...